High avidity scFv multimers; diabodies and triabodies (Q33825193)

29 July 2017

1 reference

title

High avidity scFv multimers; diabodies and triabodies (English)

1 reference

29 July 2017

Hudson PJ

1

1 reference

PubMed ID

10648937

29 July 2017

Kortt AA

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

Journal of Immunological Methods

29 July 2017

1 reference

29 July 2017

231

1 reference

29 July 2017

1-2

1 reference

29 July 2017

177-189

1 reference

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Single-chain antigen-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Construction of recombinant extended single-chain antibody peptide conjugates for use in the diagnosis of HIV-1 and HIV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Tumor-specific T-bodies: towards clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

"Diabodies": small bivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Retargeting serum immunoglobulin with bispecific diabodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Recombinant antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Recombinant antibody constructs in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Triabodies: single chain Fv fragments without a linker form trivalent trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

High level production of soluble single chain antibodies in small-scale Escherichia coli cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Complement recruitment using bispecific diabodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Enzyme immunoassays using bispecific diabodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Specific targeting of cytokine-secreting cells: a bispecific diabody recognizing human interleukin-6 and CD3 induces T cell-mediated killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Orientation of antigen binding sites in dimeric and trimeric single chain Fv antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Recombinant antineuraminidase single chain antibody: expression, characterization, and crystallization in complex with antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Three-dimensional structures of single-chain Fv-neuraminidase complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties: anti-digoxin 26-10 (sFv')2 and anti-c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through C-terminal cysteinyl peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Phage diabody repertoires for selection of large numbers of bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Model and Simulation of Multivalent Binding to Fixed Ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

A dimeric bispecific miniantibody combines two specificities with avidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Crystal structure of a diabody, a bivalent antibody fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

New protein engineering approaches to multivalent and bispecific antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Mutual Stabilization of VLand VHin Single-Chain Antibody Fragments, Investigated with Mutants Engineered for Stability†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

High level secretion of a humanized bispecific diabody from Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

Remodeling domain interfaces to enhance heterodimer formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

The development of monoclonal antibodies for the therapy of cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900157-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-1759(99)00157-X

1 reference

release_3hibwnfbubc2vkxxw2l3mwahe4

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3hibwnfbubc2vkxxw2l3mwahe4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

10648937

1 reference

PubMed ID

10648937